Cowen reiterated an Outperform rating and $216.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's 3Q earnings report. Alexion reported Q3 Soliris sales of $665.4MM vs. consensus $666MME and nonGAAP EPS of $1.16 vs. $1.01E.

Analyst Eric Schmidt commented, "Alexion reported Q3 Soliris sales of $665.4MM vs. consensus $666MME and nonGAAP EPS of $1.16 vs. $1.01E. While Soliris met expectations, incremental LatAm Fx headwinds thwarted any upside and caused Alexion to guide toward the lower end of its 2015 revenue range ($2.60-2.62B). Nonetheless, with multiple drug launches and a maturing pipeline we view ALXN as the premier orphan disease company."

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $177.41 yesterday.